Evaluation of cerebral vasoreactivity by SPECT and transcranial Doppler sonography using the acetazolamide test

L. Pávics, F. Grunwald, P. Barzó, E. Ambrus, C. Menzel, A. Schomburg, L. Borda, E. Mate, M. Bodosi, L. Csernay, H. J. Biersack

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

rCBF SPECT with 99mTc-HMPAO was performed prospectively in 29 patients (3 controls and 26 stroke patients) as well as TCD studies in 20 patients (3 controls and 17 stroke patients) before and after 1 g i.v. acetazolamide. The sensitivity of rCBF SPECT increased from 62% to 77% after acetazolamide provocation in stroke patients. In patients with a reversible neurological deficit, the sensitivity under resting conditions was 50% which increased to 71%, while in cases with a permanent deficit it increased from 75% to 83%. In the evaluation of the cerebrovascular reserve capacity the results of rCBF SPECT and TCD coincided in 91% of the hemispheres. The correlation was statistically significant.

Original languageEnglish
Pages (from-to)239-243
Number of pages5
JournalNuklearmedizin
Volume33
Issue number6
Publication statusPublished - 1994

Fingerprint

Doppler Transcranial Ultrasonography
Acetazolamide
Single-Photon Emission-Computed Tomography
Stroke
Technetium Tc 99m Exametazime

Keywords

  • acetazolamide
  • cerebrovascular disorders
  • SPECT
  • ultrasonics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Pávics, L., Grunwald, F., Barzó, P., Ambrus, E., Menzel, C., Schomburg, A., ... Biersack, H. J. (1994). Evaluation of cerebral vasoreactivity by SPECT and transcranial Doppler sonography using the acetazolamide test. Nuklearmedizin, 33(6), 239-243.

Evaluation of cerebral vasoreactivity by SPECT and transcranial Doppler sonography using the acetazolamide test. / Pávics, L.; Grunwald, F.; Barzó, P.; Ambrus, E.; Menzel, C.; Schomburg, A.; Borda, L.; Mate, E.; Bodosi, M.; Csernay, L.; Biersack, H. J.

In: Nuklearmedizin, Vol. 33, No. 6, 1994, p. 239-243.

Research output: Contribution to journalArticle

Pávics, L, Grunwald, F, Barzó, P, Ambrus, E, Menzel, C, Schomburg, A, Borda, L, Mate, E, Bodosi, M, Csernay, L & Biersack, HJ 1994, 'Evaluation of cerebral vasoreactivity by SPECT and transcranial Doppler sonography using the acetazolamide test', Nuklearmedizin, vol. 33, no. 6, pp. 239-243.
Pávics, L. ; Grunwald, F. ; Barzó, P. ; Ambrus, E. ; Menzel, C. ; Schomburg, A. ; Borda, L. ; Mate, E. ; Bodosi, M. ; Csernay, L. ; Biersack, H. J. / Evaluation of cerebral vasoreactivity by SPECT and transcranial Doppler sonography using the acetazolamide test. In: Nuklearmedizin. 1994 ; Vol. 33, No. 6. pp. 239-243.
@article{ee44fbfb756844fdb6d62484f20bfbaf,
title = "Evaluation of cerebral vasoreactivity by SPECT and transcranial Doppler sonography using the acetazolamide test",
abstract = "rCBF SPECT with 99mTc-HMPAO was performed prospectively in 29 patients (3 controls and 26 stroke patients) as well as TCD studies in 20 patients (3 controls and 17 stroke patients) before and after 1 g i.v. acetazolamide. The sensitivity of rCBF SPECT increased from 62{\%} to 77{\%} after acetazolamide provocation in stroke patients. In patients with a reversible neurological deficit, the sensitivity under resting conditions was 50{\%} which increased to 71{\%}, while in cases with a permanent deficit it increased from 75{\%} to 83{\%}. In the evaluation of the cerebrovascular reserve capacity the results of rCBF SPECT and TCD coincided in 91{\%} of the hemispheres. The correlation was statistically significant.",
keywords = "acetazolamide, cerebrovascular disorders, SPECT, ultrasonics",
author = "L. P{\'a}vics and F. Grunwald and P. Barz{\'o} and E. Ambrus and C. Menzel and A. Schomburg and L. Borda and E. Mate and M. Bodosi and L. Csernay and Biersack, {H. J.}",
year = "1994",
language = "English",
volume = "33",
pages = "239--243",
journal = "Nuklearmedizin",
issn = "0029-5566",
publisher = "Schattauer GmbH",
number = "6",

}

TY - JOUR

T1 - Evaluation of cerebral vasoreactivity by SPECT and transcranial Doppler sonography using the acetazolamide test

AU - Pávics, L.

AU - Grunwald, F.

AU - Barzó, P.

AU - Ambrus, E.

AU - Menzel, C.

AU - Schomburg, A.

AU - Borda, L.

AU - Mate, E.

AU - Bodosi, M.

AU - Csernay, L.

AU - Biersack, H. J.

PY - 1994

Y1 - 1994

N2 - rCBF SPECT with 99mTc-HMPAO was performed prospectively in 29 patients (3 controls and 26 stroke patients) as well as TCD studies in 20 patients (3 controls and 17 stroke patients) before and after 1 g i.v. acetazolamide. The sensitivity of rCBF SPECT increased from 62% to 77% after acetazolamide provocation in stroke patients. In patients with a reversible neurological deficit, the sensitivity under resting conditions was 50% which increased to 71%, while in cases with a permanent deficit it increased from 75% to 83%. In the evaluation of the cerebrovascular reserve capacity the results of rCBF SPECT and TCD coincided in 91% of the hemispheres. The correlation was statistically significant.

AB - rCBF SPECT with 99mTc-HMPAO was performed prospectively in 29 patients (3 controls and 26 stroke patients) as well as TCD studies in 20 patients (3 controls and 17 stroke patients) before and after 1 g i.v. acetazolamide. The sensitivity of rCBF SPECT increased from 62% to 77% after acetazolamide provocation in stroke patients. In patients with a reversible neurological deficit, the sensitivity under resting conditions was 50% which increased to 71%, while in cases with a permanent deficit it increased from 75% to 83%. In the evaluation of the cerebrovascular reserve capacity the results of rCBF SPECT and TCD coincided in 91% of the hemispheres. The correlation was statistically significant.

KW - acetazolamide

KW - cerebrovascular disorders

KW - SPECT

KW - ultrasonics

UR - http://www.scopus.com/inward/record.url?scp=0028641548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028641548&partnerID=8YFLogxK

M3 - Article

C2 - 7854920

AN - SCOPUS:0028641548

VL - 33

SP - 239

EP - 243

JO - Nuklearmedizin

JF - Nuklearmedizin

SN - 0029-5566

IS - 6

ER -